

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4577355

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RACHEL SOREK	08/20/2017
KEREN JAKOBI	08/20/2017
PENNINA SAFER	08/20/2017
ANAT REINER-BENAIM	08/20/2017
RECEIVING PARTY DATA	
Name:	IMMUNARRAY LTD.
Street Address:	12 HAMADA ST. ENTRANCE A
City:	REHOVOT
State/Country:	ISRAEL
Postal Code:	7670315
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15555258
CORRESPONDENCE DATA	
Fax Number:	(202)533-9187
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(202) 467-8800
Email:	lmelliott@vorys.com
Correspondent Name:	VORYS, SATER, SEYMOUR AND PEASE LLP
Address Line 1:	1909 K ST., NW
Address Line 2:	9TH FLOOR
Address Line 4:	WASHINGTON, D.C. 20006-1152
ATTORNEY DOCKET NUMBER:	068717-000094
NAME OF SUBMITTER:	ARI G. ZYT CER
SIGNATURE:	/Ari G. Zytcer/
DATE SIGNED:	09/01/2017
Total Attachments: 6	
source=Signed Assignment - inventors 1-3#page1.tif	
source=Signed Assignment - inventors 1-3#page2.tif	

source=Signed Assignment - inventors 1-3#page3.tif

source=Signed Assignment - inventor 4#page1.tif

source=Signed Assignment - inventor 4#page2.tif

source=Signed Assignment - inventor 4#page3.tif

ASSIGNMENT

This Assignment is made and executed by:

SOREK, Rachel
259 Hate'ena st.
6093200 Zafaria
Israel

JAKOBI, Keren
40 Shderot Haprahim st.
Reut-Maccabim
Israel

SAFER, Pennina
20 Gorodeski
76227 Rechovot
Israel

REINER-BENAIM, Anat
Hahagna 9
Binyamina
Israel

(hereinafter "Assignors"), to and in favor of IMMUNARRAY LTD. having a business address of 12 Hamada st. Entrance A 7670315 Rehovot, Israel (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the nonprovisional patent application for a United States Patent entitled "**DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS**" which claims priority to as a 371 of international of PCT/IL2016/050229, filed on February 29, 2016, which claims priority to US provisional patent application number 62/126,616, filed on March 1, 2015, from US provisional patent application number 62/181,231, filed on June 18, 2015 and from US provisional patent application number 62/249,284, filed on November 1, 2015 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to the Assignors;

Accordingly, Assignors each warrant, covenant and agree as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of

ASSIGNMENT

Title: "DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS"

IMNR/013 IN

priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

ASSIGNMENT

Title: "DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS"

IMNR/013 IN

20 - August 2017
Date

Rachel Sorek
SOREK, Rachel

Witness

20/8/17
Date

Keren Jakobi
JAKOBI, Keren

Witness

20th Aug 2017
Date

Pennina Safir
SAFER, Pennina

Witness

Date

REINER-BENAIM, Anat

Witness

ASSIGNMENT

This Assignment is made and executed by:

SOREK, Rachel
259 Hate'ena st.
6093200 Zafaria
Israel

JAKOBI, Keren
40 Shderot Haprahim st.
Reut-Maccabim
Israel

SAFER, Pennina
20 Gorodeski
76227 Rechovot
Israel

REINER-BENAIM, Anat
Hahagna 9
Binyamina
Israel

(hereinafter "Assignors"), to and in favor of IMMUNARRAY LTD. having a business address of 12 Hamada st. Entrance A 7670315 Rehovot, Israel (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the nonprovisional patent application for a United States Patent entitled "**DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS**" which claims priority to as a 371 of international of PCT/IL2016/050229, filed on February 29, 2016, which claims priority to US provisional patent application number 62/126,616, filed on March 1, 2015, from US provisional patent application number 62/181,231, filed on June 18, 2015 and from US provisional patent application number 62/249,284, filed on November 1, 2015 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to the Assignors;

Accordingly, Assignors each warrant, covenant and agree as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of

ASSIGNMENT

Title: "DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS"

IMNR/013 IN

priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

ASSIGNMENT

Title: "DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING PROTEIN, PEPTIDE AND OLIGONUCLEOTIDE ANTIGENS"

IMNR/013 IN

Date

SOREK, Rachel

Witness

Date

JAKOBI, Keren

Witness

Date

SAFER, Pennina

Witness

2018/17
Date


REINER-BENAIM, Anat

Witness